S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.58 (+0.33%)
AAPL   174.09 (-0.26%)
MSFT   290.09 (-0.42%)
META   174.55 (-0.17%)
GOOGL   120.10 (+0.46%)
AMZN   142.34 (+0.17%)
TSLA   908.45 (-0.39%)
NVDA   187.80 (+2.43%)
NIO   19.87 (-1.05%)
BABA   90.71 (+1.05%)
AMD   100.49 (+2.26%)
MU   63.08 (+2.37%)
T   18.40 (-0.11%)
CGC   3.80 (-6.40%)
F   16.14 (+0.69%)
GE   79.23 (-0.86%)
DIS   122.55 (-0.21%)
AMC   19.06 (-10.77%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.83 (+1.53%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.58 (+0.33%)
AAPL   174.09 (-0.26%)
MSFT   290.09 (-0.42%)
META   174.55 (-0.17%)
GOOGL   120.10 (+0.46%)
AMZN   142.34 (+0.17%)
TSLA   908.45 (-0.39%)
NVDA   187.80 (+2.43%)
NIO   19.87 (-1.05%)
BABA   90.71 (+1.05%)
AMD   100.49 (+2.26%)
MU   63.08 (+2.37%)
T   18.40 (-0.11%)
CGC   3.80 (-6.40%)
F   16.14 (+0.69%)
GE   79.23 (-0.86%)
DIS   122.55 (-0.21%)
AMC   19.06 (-10.77%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.83 (+1.53%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.58 (+0.33%)
AAPL   174.09 (-0.26%)
MSFT   290.09 (-0.42%)
META   174.55 (-0.17%)
GOOGL   120.10 (+0.46%)
AMZN   142.34 (+0.17%)
TSLA   908.45 (-0.39%)
NVDA   187.80 (+2.43%)
NIO   19.87 (-1.05%)
BABA   90.71 (+1.05%)
AMD   100.49 (+2.26%)
MU   63.08 (+2.37%)
T   18.40 (-0.11%)
CGC   3.80 (-6.40%)
F   16.14 (+0.69%)
GE   79.23 (-0.86%)
DIS   122.55 (-0.21%)
AMC   19.06 (-10.77%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.83 (+1.53%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.58 (+0.33%)
AAPL   174.09 (-0.26%)
MSFT   290.09 (-0.42%)
META   174.55 (-0.17%)
GOOGL   120.10 (+0.46%)
AMZN   142.34 (+0.17%)
TSLA   908.45 (-0.39%)
NVDA   187.80 (+2.43%)
NIO   19.87 (-1.05%)
BABA   90.71 (+1.05%)
AMD   100.49 (+2.26%)
MU   63.08 (+2.37%)
T   18.40 (-0.11%)
CGC   3.80 (-6.40%)
F   16.14 (+0.69%)
GE   79.23 (-0.86%)
DIS   122.55 (-0.21%)
AMC   19.06 (-10.77%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.83 (+1.53%)

Invitae - NVTA Stock Forecast, Price & News

$3.84
-0.41 (-9.65%)
(As of 08/18/2022 04:20 PM ET)
Add
Compare
Today's Range
$3.71
$4.31
50-Day Range
$1.90
$8.63
52-Week Range
$1.83
$32.93
Volume
592,074 shs
Average Volume
37.24 million shs
Market Capitalization
$903.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.56

Invitae MarketRank™ Forecast

Analyst Rating
Hold
1.82 Rating Score
Upside/​Downside
253.2% Upside
$13.56 Price Target
Short Interest
Bearish
22.01% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
0.46mentions of Invitae in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$9,336 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.47) to ($1.84) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

169th out of 1,119 stocks

Medical Laboratories Industry

5th out of 28 stocks

NVTA stock logo

About Invitae (NYSE:NVTA) Stock

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Invitae Stock Down 4.5 %

Shares of Invitae stock opened at $4.25 on Thursday. The company has a debt-to-equity ratio of 4.12, a current ratio of 6.42 and a quick ratio of 6.07. The company has a 50-day moving average of $2.80 and a 200 day moving average of $5.58. The firm has a market cap of $999.90 million, a price-to-earnings ratio of -0.32 and a beta of 1.82. Invitae has a 1 year low of $1.83 and a 1 year high of $32.93.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on NVTA. Raymond James cut shares of Invitae from an "outperform" rating to a "market perform" rating in a research report on Thursday, July 21st. Benchmark lowered shares of Invitae from a "buy" rating to a "hold" rating in a report on Tuesday, July 19th. Cowen lowered shares of Invitae from an "outperform" rating to a "market perform" rating in a report on Tuesday, July 26th. JPMorgan Chase & Co. lowered shares of Invitae from a "neutral" rating to an "underweight" rating in a report on Wednesday, August 10th. Finally, SVB Leerink lowered shares of Invitae from an "outperform" rating to a "market perform" rating in a report on Tuesday, July 19th. Two research analysts have rated the stock with a sell rating and nine have given a hold rating to the company's stock. According to data from MarketBeat.com, Invitae has an average rating of "Hold" and an average price target of $13.56.

Receive NVTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

NVTA Stock News Headlines

Why Invitae Corporation Could Underperform
Is Soaring Invitae Stock a Smart Buy Now?
Invitae Sees Unusually Large Options Volume (NYSE:NVTA)
Why Invitae Stock Is Skyrocketing Today
Invitae: Q2 Earnings Insights - Benzinga
Invitae (NVTA) Reports Q2 Loss, Lags Revenue Estimates
Invitae (NVTA) Set to Announce Earnings on Tuesday
What's Next for Invitae?
What's Next for Invitae? - TheStreet
See More Headlines
Receive NVTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

NVTA Company Calendar

Last Earnings
11/07/2021
Today
8/18/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
3,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.56
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+253.2%
Consensus Rating
Hold
Rating Score (0-4)
1.82
Research Coverage
11 Analysts

Profitability

Net Income
$-379,010,000.00
Net Margins
-620.70%
Pretax Margin
-631.07%

Debt

Sales & Book Value

Annual Sales
$460.45 million
Book Value
$1.64 per share

Miscellaneous

Free Float
232,678,000
Market Cap
$903.44 million
Optionable
Optionable
Beta
1.82














NVTA Stock - Frequently Asked Questions

Should I buy or sell Invitae stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last year. There are currently 2 sell ratings and 9 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVTA, but not buy additional shares or sell existing shares.
View NVTA analyst ratings
or view top-rated stocks.

What is Invitae's stock price forecast for 2022?

11 Wall Street research analysts have issued 12-month price objectives for Invitae's shares. Their NVTA share price forecasts range from $2.25 to $25.00. On average, they expect the company's stock price to reach $12.31 in the next year. This suggests a possible upside of 189.5% from the stock's current price.
View analysts price targets for NVTA
or view top-rated stocks among Wall Street analysts.

How have NVTA shares performed in 2022?

Invitae's stock was trading at $15.27 at the beginning of 2022. Since then, NVTA stock has decreased by 72.2% and is now trading at $4.25.
View the best growth stocks for 2022 here
.

When is Invitae's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our NVTA earnings forecast
.

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) issued its quarterly earnings data on Sunday, November, 7th. The medical research company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.69) by $0.22. The medical research company had revenue of $114.40 million for the quarter, compared to analyst estimates of $126.56 million. Invitae had a negative net margin of 620.70% and a negative trailing twelve-month return on equity of 29.91%. The business's quarterly revenue was up 66.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.62) earnings per share.

What guidance has Invitae issued on next quarter's earnings?

Invitae issued an update on its second quarter 2022 earnings guidance on Tuesday, August, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $136.00 million-$136.00 million, compared to the consensus revenue estimate of $142.74 million.

What is Sean George's approval rating as Invitae's CEO?

59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

When did Invitae IPO?

(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is Invitae's stock symbol?

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Who are Invitae's major shareholders?

Invitae's stock is owned by many different retail and institutional investors. Top institutional investors include ARK Investment Management LLC (12.50%), Sumitomo Mitsui Trust Holdings Inc. (7.64%), Nikko Asset Management Americas Inc. (7.64%), Northern Trust Corp (0.93%), JPMorgan Chase & Co. (0.63%) and Renaissance Technologies LLC (0.59%). Insiders that own company stock include Artur Bergman, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Randal W Scott, Robert F Werner, Robert F Werner, Robert L Nussbaum, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer, Thomas Brida and Yafei Wen.
View institutional ownership trends
.

How do I buy shares of Invitae?

Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Invitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $4.25.

How much money does Invitae make?

Invitae (NYSE:NVTA) has a market capitalization of $999.90 million and generates $460.45 million in revenue each year. The medical research company earns $-379,010,000.00 in net income (profit) each year or ($13.48) on an earnings per share basis.

How many employees does Invitae have?

The company employs 3,000 workers across the globe.

How can I contact Invitae?

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The official website for the company is www.invitae.com. The medical research company can be reached via phone at (415) 374-7782 or via email at ir@invitae.com.

This page (NYSE:NVTA) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.